Curium to acquire Lantheus for up to $114.50/share ($8.0B); 38% premium to 60-day VWAP

Lantheus Holdings, Inc.

• Total consideration up to $114.50/share: $102.50 cash at closing plus up to $12.00 in CVRs tied to commercial milestones through 2030.
• Aggregate transaction value up to $8.0B; premiums of 38% (60-day VWAP), 29% (30-day VWAP), and 21% (unaffected close).
• Lantheus Board unanimously approved; transaction expected to close in first half of 2027, subject to shareholder and regulatory approvals.
• Lantheus pauses CEO search, suspends FY2026 guidance, and will not host Q2 2026 earnings call due to pending merger.
• Combined company will serve oncology, neurology, and cardiology patients across more than 70 countries.